Primary resistance to imatinib in Fip1-like 1–platelet-derived growth factor receptor α—positive eosinophilic leukemia
- 30 April 2008
- journal article
- other
- Published by Elsevier in Journal of Allergy and Clinical Immunology
- Vol. 121 (4) , 1054-1056
- https://doi.org/10.1016/j.jaci.2007.11.027
Abstract
No abstract availableKeywords
This publication has 10 references indexed in Scilit:
- The FIP1L1-PDGFRA fusion gene cooperates with IL-5 to induce murine hypereosinophilic syndrome (HES)/chronic eosinophilic leukemia (CEL)–like diseaseBlood, 2006
- Safety and efficacy of the monoclonal anti–interleukin-5 antibody SCH55700 in the treatment of patients with hypereosinophilic syndromeBlood, 2004
- Molecular remission and reversal of myelofibrosis in response to imatinib mesylate treatment in patients with the myeloproliferative variant of hypereosinophilic syndromeBlood, 2004
- Mechanisms and implications of imatinib resistance mutations in BCR-ABLCurrent Opinion in Hematology, 2004
- Use of an Anti–Interleukin-5 Antibody in the Hypereosinophilic Syndrome with Eosinophilic DermatitisNew England Journal of Medicine, 2003
- A Tyrosine Kinase Created by Fusion of thePDGFRAandFIP1L1Genes as a Therapeutic Target of Imatinib in Idiopathic Hypereosinophilic SyndromeNew England Journal of Medicine, 2003
- Interleukin‐2 primes eosinophil degranulation in hypereosinophilia and Wells' syndromeEuropean Journal of Immunology, 2003
- Mechanisms of Autoinhibition and STI-571/Imatinib Resistance Revealed by Mutagenesis of BCR-ABLCell, 2003
- Treatment of hypereosinophilic syndrome with imatinib mesilateThe Lancet, 2002
- Abnormal Clones of T Cells Producing Interleukin-5 in Idiopathic EosinophiliaNew England Journal of Medicine, 1999